Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

Completed · Phase 2

Conditions studied: Parkinson Disease

In brief

The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in the study called, A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson's Disease - (PRECEPT), sponsored by Cephalon and Lundbeck and coordinated by the Parkinson Study Group. The imaging data from this long-term PRECEPT follow-up study will allow us to evaluate the long-term progression of DAT loss in PD, the long-term follow-up of SWEDD subjects, the relationship between long-term clinical and imaging PD outcomes, and the relationship between long-term imaging outcomes and genetic and biochemical biomarkers of PD progression.

Key facts

Study ID: NCT00404170
Run by: Institute for Neurodegenerative Disorders
People needed: 396
Starts: 2006-11-01
Expected to finish: 2014-07-01
Last updated by the study team: 2022-07-05

Who can join

Age: 30 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject was a participant in the PRECEPT clinical and imaging study
Participant must be willing and able to comply with study procedures
Participant must be willing and able to give informed consent.

You may not qualify if…

The participant has a clinically significant clinical laboratory value and/or medical or psychiatric illness
The participant has dementia (MMSE≤24)
Pregnancy

Where it is running

Institute for Neurodegenerative Disorders — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.